{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:10:37Z","timestamp":1792789837568,"version":"4.5.0"},"reference-count":40,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802605"],"award-info":[{"award-number":["81802605"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["ZC20144"],"award-info":[{"award-number":["ZC20144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21JCQNJC00230"],"award-info":[{"award-number":["21JCQNJC00230"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["TJYXZDXK-043A"],"award-info":[{"award-number":["TJYXZDXK-043A"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Project of Tianjin Health Committee","award":["81802605"],"award-info":[{"award-number":["81802605"]}]},{"name":"Science and Technology Project of Tianjin Health Committee","award":["ZC20144"],"award-info":[{"award-number":["ZC20144"]}]},{"name":"Science and Technology Project of Tianjin Health Committee","award":["21JCQNJC00230"],"award-info":[{"award-number":["21JCQNJC00230"]}]},{"name":"Science and Technology Project of Tianjin Health Committee","award":["TJYXZDXK-043A"],"award-info":[{"award-number":["TJYXZDXK-043A"]}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Planning Project","doi-asserted-by":"publisher","award":["81802605"],"award-info":[{"award-number":["81802605"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Planning Project","doi-asserted-by":"publisher","award":["ZC20144"],"award-info":[{"award-number":["ZC20144"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Planning Project","doi-asserted-by":"publisher","award":["21JCQNJC00230"],"award-info":[{"award-number":["21JCQNJC00230"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Planning Project","doi-asserted-by":"publisher","award":["TJYXZDXK-043A"],"award-info":[{"award-number":["TJYXZDXK-043A"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["81802605"],"award-info":[{"award-number":["81802605"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["ZC20144"],"award-info":[{"award-number":["ZC20144"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["21JCQNJC00230"],"award-info":[{"award-number":["21JCQNJC00230"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["TJYXZDXK-043A"],"award-info":[{"award-number":["TJYXZDXK-043A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Background: Anlotinib is a highly potent multi-target tyrosine kinase inhibitor. Accumulating evidence suggests that anlotinib exhibits effective anti-tumor activity against various cancer subtypes. However, the effects of anlotinib against cisplatin-resistant (CIS) ovarian cancer (OC) are yet to be elucidated. The objective of this study was to investigate the inhibitory effect of anlotinib on the pathogenesis of cisplatin-resistant OC. Materials and Methods: Human OC cell lines (A2780 and A2780 CIS) were cultured and treated with or without anlotinib. The effects of anlotinib on cell proliferation were determined using cell-counting kit-8 and colony-formation assays. To evaluate the invasion and metastasis of OC cells, we performed wound-healing and transwell assays. The cell cycle was analyzed via flow cytometry. A xenograft mouse model was used to conduct in vivo studies to verify the effects of anlotinib. The expression of Ki-67 in the tumor tissue was detected via immunohistochemistry. Quantitative real-time polymerase chain reaction and Western blotting were used to measure the mRNA and protein levels. Results: Our study revealed that anlotinib significantly inhibited the proliferation, migration, and invasion of A2780 and A2780 CIS in a dose-dependent way in vitro (p &lt; 0.05). Through R software \u2018limma\u2019 package analysis of GSE15372, it was found that, in comparison with A2780, PLK2 was expressed in significantly low levels in the corresponding cisplatin-resistant strains. The ERK1\/2\/Plk2 signaling axis mediates the inhibitory effect of anlotinib on the proliferation and migration of ovarian cancer cell lines. Moreover, our research found that anlotinib effectively inhibited the growth of tumor cells in an OC xenograft mouse model. Conclusions: In this study, anlotinib showed excellent inhibitory effects against cisplatin-resistant OC both in vitro and in vivo. These results add to the growing body of evidence supporting anlotinib as a potential anticancer agent against OC.<\/jats:p>","DOI":"10.3390\/molecules27248873","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T03:21:52Z","timestamp":1670988112000},"page":"8873","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7563-4794","authenticated-orcid":false,"given":"Yurou","family":"Ji","sequence":"first","affiliation":[{"name":"Clinical School of Obstetrics and Gynecology Center, Tianjin Medical University, Tianjin 300100, China"},{"name":"Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical School of Obstetrics and Gynecology Center, Tianjin Medical University, Tianjin 300100, China"},{"name":"Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Qi","sequence":"additional","affiliation":[{"name":"Clinical School of Obstetrics and Gynecology Center, Tianjin Medical University, Tianjin 300100, China"},{"name":"Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Clinical School of Obstetrics and Gynecology Center, Tianjin Medical University, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-9280","authenticated-orcid":false,"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical School of Obstetrics and Gynecology Center, Tianjin Medical University, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Qu","sequence":"additional","affiliation":[{"name":"Clinical School of Obstetrics and Gynecology Center, Tianjin Medical University, Tianjin 300100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/ijc.30676","article-title":"International patterns and trends in ovarian cancer incidence, overall and by histologic subtype","volume":"140","author":"Coburn","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2006.03.011","article-title":"Systemic therapy for ovarian cancer: Current status and new treatments","volume":"33","author":"Ozols","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102111","DOI":"10.1016\/j.ctrv.2020.102111","article-title":"Newly diagnosed ovarian cancer: Which first-line treatment?","volume":"91","author":"Lorusso","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"i63","DOI":"10.1093\/annonc\/mdw079","article-title":"Recurrent ovarian cancer","volume":"27","author":"Combe","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1758835918768232","DOI":"10.1177\/1758835918768232","article-title":"First-line treatment of ovarian cancer: Questions and controversies to address","volume":"10","author":"Ledermann","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"Kristensen","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(18)30349-8","article-title":"Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): A phase 2, single-arm, prospective study","volume":"19","author":"Lan","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/cas.13536","article-title":"Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","article-title":"Anlotinib: First Global Approval","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.32180","article-title":"Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma","volume":"145","author":"Wang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2018.5526","article-title":"Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China","volume":"5","author":"Chen","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.20892\/j.issn.2095-3941.2020.0024","article-title":"Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling","volume":"17","author":"Qin","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","article-title":"Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/ERC-17-0558","article-title":"Antitumor effects of anlotinib in thyroid cancer","volume":"26","author":"Ruan","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","article-title":"Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma","volume":"28","author":"Su","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"937924","DOI":"10.3389\/fimmu.2022.937924","article-title":"Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy","volume":"13","author":"Fan","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5479491","DOI":"10.1155\/2022\/5479491","article-title":"Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer","volume":"2022","author":"Yuan","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102076","DOI":"10.1016\/j.redox.2021.102076","article-title":"The cross-talk between tumor cells and activated fibroblasts mediated by lactate\/BDNF\/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer","volume":"46","author":"Jin","year":"2021","journal-title":"Redox Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jgg.2021.06.014","article-title":"Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma","volume":"48","author":"Huang","year":"2021","journal-title":"J. Genet Genom."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e20053","DOI":"10.1097\/MD.0000000000020053","article-title":"Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report","volume":"99","author":"Sun","year":"2020","journal-title":"Medicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100689","DOI":"10.1016\/j.xcrm.2022.100689","article-title":"Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial","volume":"3","author":"Lan","year":"2022","journal-title":"Cell Rep. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1158\/0008-5472.CAN-10-2048","article-title":"Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer","volume":"71","author":"Syed","year":"2011","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2011.01.026","article-title":"Chemotherapy in epithelial ovarian cancer","volume":"303","author":"Pignata","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1749-6632.2012.06734.x","article-title":"Molecular determinants of ovarian cancer chemoresistance: New insights into an old conundrum","volume":"1271","author":"Ali","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.bbrc.2018.08.098","article-title":"Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway","volume":"503","author":"He","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"798837","DOI":"10.3389\/fphar.2021.798837","article-title":"Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/DDDT.S286529","article-title":"A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer","volume":"15","author":"Cui","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3727\/096504009789954672","article-title":"Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays","volume":"18","author":"Ju","year":"2009","journal-title":"Oncol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Szenajch, J., Szabelska-Ber\u0119sewicz, A., \u015awiercz, A., Zyprych-Walczak, J., Siatkowski, I., G\u00f3ralski, M., Synowiec, A., and Handschuh, L. (2020). Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239218"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kressin, M., Fietz, D., Becker, S., and Strebhardt, K. (2021). Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer. Cells, 10.","DOI":"10.3390\/cells10051176"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fonc.2019.00476","article-title":"Transcriptional Activation of by MEK\/ERK Signaling Confers Chemo-Resistance to Cisplatin in Lung Cancer Stem Cells","volume":"9","author":"Li","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2343876","DOI":"10.1155\/2019\/2343876","article-title":"Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK\/MEK Pathway","volume":"2019","author":"Kulshrestha","year":"2019","journal-title":"J. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.3802\/jgo.2022.33.e75","article-title":"SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1\/IGF2\/MEK\/ERK axis","volume":"33","author":"Zhu","year":"2022","journal-title":"J. Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"826716","DOI":"10.3389\/fphar.2022.826716","article-title":"Sporoderm-Broken Spores of Sensitizes Ovarian Cancer to Cisplatin by ROS\/ERK Signaling and Attenuates Chemotherapy-Related Toxicity","volume":"13","author":"Cen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Parashar, D., Geethadevi, A., Mittal, S., McAlarnen, L.A., George, J., Kadamberi, I.P., Gupta, P., Uyar, D.S., Hopp, E.E., and Drendel, H. (2022). Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers, 14.","DOI":"10.3390\/cancers14040958"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11933","DOI":"10.1158\/0008-5472.CAN-07-5185","article-title":"ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Res."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/24\/8873\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:40:51Z","timestamp":1760146851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/24\/8873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":40,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["molecules27248873"],"URL":"https:\/\/doi.org\/10.3390\/molecules27248873","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]}}}